Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
Westwood Holdings Group Inc CFO Forbes Murray III completed offsetting transactions on February 23, 2026, selling 2,859 shares at $16.22 and purchasing 11,098 shares the same day. After the trades he holds 65,826 shares. The firm reported year-over-year revenue growth in Q4 2025 and a modest post-report stock dip, while market metrics show a $134 m…
C3.ai Executive Chairman Thomas M. Siebel sold 23,435 shares of Class A common stock on March 12, 2026, for roughly $213,492, after receiving 44,766 shares from vested restricted stock units the prior day. The transactions come as the stock trades near multi-quarter lows and the company confronts significant revenue misses, reduced guidance and a s…
Control Empresarial de Capitales S.A. de C.V., a roughly 10% shareholder of PBF Energy Inc (NYSE:PBF), disposed of 645,000 Class A shares over March 12-13, 2026, realizing $27,993,833 at prices between $42.9901 and $43.785, according to a Form 4 filed with the Securities and Exchange Commission. The transactions reduced the entity's holding to 24,7…
Gogo Inc. director Charles C. Townsend purchased a total of 250,000 shares across two trades on March 11 and March 12, 2026, investing $1.13 million at weighted average prices. The purchases come while the stock trades at $4.31, far below its 52-week high of $16.82, and after a fourth-quarter 2025 report that missed EPS expectations but beat revenu…
Raymond John W, a director and special advisor at IonQ Inc (NYSE: IONQ), executed a sale of 2,800 common shares on March 12, 2026, for $33.34 each, yielding $93,352, according to a Form 4 filed with the SEC. After the sale he holds 83,963 shares. The quantum computing company has seen shares trade near $32.98 while delivering a 32% return over the …
Amanda Whalen, Chief Financial Officer of Klaviyo, Inc. (KVYO), sold 14,000 shares of Series A Common Stock on March 12, 2026, generating $274,150 in proceeds through two transactions executed under a Rule 10b5-1 plan. The trades took place as Klaviyo’s shares traded near $19.12, below an InvestingPro Fair Value estimate of $24.51. Separately, the …
Klaviyo Chief Legal Officer Edmond Landon sold 14,366 shares of the company's Series A Common Stock on March 12, 2026, for about $289,474 under a Rule 10b5-1 plan. The transaction leaves Landon with 312,362 shares, including 228,407 unvested restricted stock units. Separately, Klaviyo announced a $500 million share repurchase program with an initia…
Angela Brock-Kyle, a member of Kelly Services Inc.'s board, purchased 100 shares of the company's Class B Common Stock on March 4, 2026, for $14.77 per share, an investment totaling $1,477. The stock has since fallen to $8.53 and sits close to its 52-week low. Concurrently, Kelly has named a new divisional president and its board instituted a stock…
Adaptive Biotechnologies President and COO Julie Rubinstein sold 159,243 shares of common stock between March 11 and March 13, 2026, producing about $2.37 million in proceeds, and exercised options to acquire an additional 44,166 shares. The transactions were executed under a Rule 10b5-1 plan adopted November 18, 2025, as the stock trades around $1…
ACM Research Inc.'s Chief Financial Officer and Treasurer, Mark McKechnie, sold 98,342 shares of Class A common stock on March 12, 2026, through transactions under a pre-arranged Rule 10b5-1 plan adopted August 27, 2025. The sales totaled about $4.49 million at per-share prices between $44.89 and $46.57. On the same day he exercised options to acqu…
Mathi Gurusamy, Chief Product & Strategy Officer at Lantronix Inc. (LTRX), sold 14,467 shares of common stock on March 13, 2026, for about $89,840 at prices between $6.21 and $6.28. After the trade Gurusamy holds 55,569 shares directly. Separately, Lantronix reported fiscal 2026 second-quarter results with EPS of $0.04 versus the $0.03 forecast and…
Adaptive Biotechnologies director Michelle Renee Griffin reported the sale of 15,394 shares on March 11, 2026, in a Form 4 filing with the SEC. The shares were sold at a weighted-average price of $13.91 for a total of $214,130. The transaction occurred as the stock traded at $13.17, a level InvestingPro considers above Fair Value. The company also …
Adaptive Biotechnologies Chief Financial Officer Kyle Piskel sold 18,672 shares on March 11, 2026, at $13.17 per share, generating $245,910. The sale was a mandated "sell to cover" to meet tax withholding tied to restricted stock unit vesting. The company’s stock has shown sharp short-term weakness despite a sizable 12-month gain, and InvestingPro …
Dianthus Therapeutics CEO Marino Garcia sold 122,918 shares on March 12, 2026, for roughly $10 million under a pre-arranged 10b5-1 plan and exercised options to acquire the same number of shares at $6.70 per share. The transactions coincide with a string of large equity raises and favorable interim data from the company’s Phase 3 CAPTIVATE trial, e…
Susan Bobulsky, Adaptive Biotechnologies' Chief Commercial Officer for MRD, sold 41,338 shares on March 11, 2026, at $13.17 per share for $544,421 to cover tax withholding on vested RSUs. The transaction follows a week of stock weakness and comes after the company reported stronger-than-expected fourth-quarter 2025 results and received several anal…
Adaptive Biotechnologies Chief Commercial Officer Sharon Benzeno sold 63,103 shares on March 11, 2026, for $13.17 per share, totaling $831,066. The sale was executed to meet tax withholding obligations tied to vesting restricted stock units under the company’s equity incentive plans. The transaction occurs after a recent 11% slide in the stock over…
Director Neil Mehta filed purchases of 7,350,104 Coupang Class A shares valued at $136.5 million in three transactions reported on a Form 4 with the SEC. The buys took place March 11-13, 2026, and follow a roughly 43% decline in the stock over the prior six months. The company reported Q4 2025 results that missed revenue and EPS expectations and dr…
Adaptive Biotechnologies executive Francis Lo sold 30,593 shares on March 11, 2026, for $430,749 under a Rule 10b5-1 plan. The transaction leaves Lo with 291,374 directly held shares and 2,500 indirectly held through a spouse. The stock has shown short-term weakness but strong one-year gains, while the company reported Q4 2025 results that beat est…
Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, sold 470,266 shares of company stock on March 11, 2026, for roughly $6.19 million. The two transactions were executed at $13.17 per share and were mandated by the company to satisfy tax withholding tied to vested restricted stock units and performance share units. The stock…
Nias James, chief accounting officer at nLIGHT, sold 1,808 shares on March 12, 2026, for a total of $116,471 under a pre-established Rule 10b5-1 plan. The disposition took place while the stock traded close to its 52-week peak following a year of substantial gains. Recent quarterly results and analyst price-target increases have highlighted the com…
Adaptive Biotechnologies Chief Executive Officer and Chairman Chad M. Robins completed two mandated sales of company shares on March 11, 2026, totaling 470,167 shares at $13.17 each, equal to roughly $6.19 million. The filings disclose the sales were to satisfy tax withholding obligations from vested restricted stock and performance share units and…
nLIGHT, Inc. director Raymond A. Link sold 25,404 shares of common stock between March 11 and March 13, 2026, for roughly $1.6 million under a Rule 10b5-1 plan adopted in December 2025. The transactions occurred while the stock traded close to its 52-week high following substantial year-over-year gains and better-than-expected fourth-quarter result…
Simrat Randhawa, Executive Vice President and Head of R&D at Dianthus Therapeutics, sold 33,830 shares for $2,756,468 and exercised options to acquire the same number of shares on March 12, 2026. The activity took place as the company completed a major public offering that raised about $719 million and after several analyst firms raised price targe…
Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, sold 43,682 shares of the company’s common stock on March 12, 2026, generating about $3.56 million. On the same day he exercised options to acquire an equal number of shares at exercise prices between $17.88 and $22.07. The transactions take place as Dianthus stock has climbed sharply …
Symbotic Inc. director Saintil Merline filed a Form 4 showing two planned sales on March 11, 2026 that disposed of 3,414 shares of Class A common stock for about $173,483. The transactions occurred under a pre-arranged trading plan. The insider sale comes as the stock trades below the sale prices while the company reports mixed quarterly results an…
